Lundbeck Advances Parkinson's Research with New Data on Lu AF28996

H. Lundbeck A/S has recently released exciting findings from an open-label Phase Ib trial focused on Lu AF28996, a novel oral prodrug designed for patients struggling with advanced Parkinson's disease. The results were presented at the prestigious MDS 2026 conference in Seoul, South Korea. This investigational drug aims to address the difficulties experienced by patients whose motor symptoms remain inadequately controlled, even after optimizing non-invasive antiparkinsonian therapies.

Parkinson's disease is notorious for its progressive degeneration of dopamine-producing neurons, leading to motor and non-motor complications that severely affect quality of life. While levodopa has long been the primary treatment for alleviating symptoms, many patients still contend with troublesome motor fluctuations and involuntary movements, commonly referred to as dyskinesia. These problems can significantly impede daily activities, necessitating innovative solutions.

The Phase Ib trial showed that Lu AF28996 was generally safe and well-tolerated, with most treatment-emergent adverse events classified as mild. The data indicated meaningful improvements in patient symptoms, with participants experiencing increased amounts of 'Good ON-time'—the periods where symptoms are effectively managed—and a notable reduction in 'OFF-time'—where symptoms exacerbate. These encouraging results were accompanied by decreases in the severity of dyskinesia as well.

The trial involved 34 participants, who were administered Lu AF28996 twice daily. After six weeks, significant changes were observed: Good ON-time increased by around 3.6 hours, while OFF-time saw a reduction of roughly 2.3 hours. Additionally, those with troublesome dyskinesia experienced a reduction in daily time affected by these involuntary movements. This is crucial information, as it laid the groundwork for further evaluations of this drug in larger cohort studies.

According to Tarek Samad, Executive Vice President at Lundbeck, these initial findings with Lu AF28996 are promising.